Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 3
Submit an article Journal homepage
1,807
Views
2
CrossRef citations to date
0
Altmetric
Articles

Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice

S. Atalaya Department of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-9671-0386
ORCID Icon,
J. M. P. A. van den Reeka Department of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3642-2673
ORCID Icon,
J. M. M. Groenewoudb Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-4974-150X
ORCID Icon,
P. C. M. van de Kerkhofa Department of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-0084-3131
ORCID Icon,
W. Kievitb Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-3984-1769
ORCID Icon &
E. M. G. J. de Jonga Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands;c Radboud University, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-3872-5704
ORCID Icon
Pages 1591-1597 | Received 19 Nov 2020, Accepted 15 Dec 2020, Published online: 07 Jan 2021

References

  • Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102–113.
  • Ronholt K, Iversen L. Old and new biological therapies for psoriasis. IJMS. 2017;18(11):2297.
  • Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet (London, England). 2007;370(9583):263–271.
  • Griffiths CEM, Augustin M, Naldi L, et al. Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. J Eur Acad Dermatol Venereol. 2018;32(9):1523–1529.
  • Atalay S, van den Reek J, den Broeder AA, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2020;156(4):393.
  • Atalay S, van den Reek J, van Vugt LJ, et al. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. BMC Dermatol. 2017;17(1):6.
  • Zweegers J, Groenewoud JMM, van den Reek J, et al. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol. 2017;176(4):1001–1009.
  • Hansel K, Bianchi L, Lanza F, et al. Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance. Acta Derm Venerol. 2017;97(3):346–350.
  • Esposito M, Gisondi P, Conti A, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31(5):863–869.
  • van Bezooijen JS, van Doorn MBA, Schreurs MWJ, et al. Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study. Ther Drug Monit. 2017;39(4):379–386.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.